Related references
Note: Only part of the references are listed.A phase 1b study of transforming growth factor-beta receptor I inhibitor galunisertib in combination with sorafenib in Japanese patients with unresectable hepatocellular carcinoma
Masafumi Ikeda et al.
INVESTIGATIONAL NEW DRUGS (2019)
First-in-class immune-modulating small molecule Icaritin in advanced hepatocellular carcinoma: preliminary results of safety, durable survival and immune biomarkers
Ying Fan et al.
BMC CANCER (2019)
Temporal trends in liver cancer mortality by educational attainment in the United States, 2000-2015
Jiemin Ma et al.
CANCER (2019)
Novel transforming growth factor beta receptor I kinase inhibitor galunisertib (LY2157299) in advanced hepatocellular carcinoma
Sandrine Faivre et al.
LIVER INTERNATIONAL (2019)
Combined Antitumor Effects of Sorafenib and GPC3-CAR T Cells in Mouse Models of Hepatocellular Carcinoma
Xiuqi Wu et al.
MOLECULAR THERAPY (2019)
Next-Generation Cancer Immunotherapy Targeting Glypican-3
Yasuhiro Shimizu et al.
FRONTIERS IN ONCOLOGY (2019)
Endothelial Cell-Derived TGF-β Promotes Epithelial-Mesenchymal Transition via CD133 in HBx-Infected Hepatoma Cells
Preety Rawal et al.
FRONTIERS IN ONCOLOGY (2019)
FGF19-FGFR4 Signaling in Hepatocellular Carcinoma
Aroosha Raja et al.
CELLS (2019)
Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next-Generation Sequencing for Matching Patients to Targeted and Immune Therapies
James J. Harding et al.
CLINICAL CANCER RESEARCH (2019)
Infigratinib Mediates Vascular Normalization, Impairs Metastasis, and Improves Chemotherapy in Hepatocellular Carcinoma
Hung Huynh et al.
HEPATOLOGY (2019)
Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial
Andrew X. Zhu et al.
LANCET ONCOLOGY (2019)
Activation of MET promotes resistance to sorafenib in hepatocellular carcinoma cells via the AKT/ERK1/2-EGR1 pathway
Qing-Feng Xiang et al.
ARTIFICIAL CELLS NANOMEDICINE AND BIOTECHNOLOGY (2019)
Evaluation of a locked nucleic acid form of antisense oligo targeting HIF-1α in advanced hepatocellular carcinoma
Jennifer Wu et al.
WORLD JOURNAL OF CLINICAL ONCOLOGY (2019)
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
Masatoshi Kudo et al.
LANCET (2018)
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
Andrew X. Zhu et al.
LANCET ONCOLOGY (2018)
Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study
Lorenza Rimassa et al.
LANCET ONCOLOGY (2018)
Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
G. K. Abou-Alfa et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Gut microbiome-mediated bile acid metabolism regulates liver cancer via NKT cells
Chi Ma et al.
SCIENCE (2018)
FT-2102, an IDH1m Inhibitor, in Combination with Azacitidine in Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Ayndrome (MDS): Results from a Phase 1 Study
Jorge E. Cortes et al.
BLOOD (2018)
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
Jordi Bruix et al.
LANCET (2017)
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
Anthony B. El-Khoueiry et al.
LANCET (2017)
Safety and Efficacy of Intratumoral Injections of Chimeric Antigen Receptor (CAR) T Cells in Metastatic Breast Cancer
Julia Tchou et al.
CANCER IMMUNOLOGY RESEARCH (2017)
The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level Results From the Global Burden of Disease Study 2015
Tomi Akinyemiju et al.
JAMA ONCOLOGY (2017)
A First-in-Human Phase I Study of the Anticancer Stem Cell Agent Ipafricept (OMP-54F28), a Decoy Receptor for Wnt Ligands, in Patients with Advanced Solid Tumors
Antonio Jimeno et al.
CLINICAL CANCER RESEARCH (2017)
Final phase Ib data for the oral c-Met inhibitor tepotinib in patients with previously treated advanced hepatocellular carcinoma.
Sandrine J. Faivre et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
H3B-6527 Is a Potent and Selective Inhibitor of FGFR4 in FGF19-Driven Hepatocellular Carcinoma
Jaya Julie Joshi et al.
CANCER RESEARCH (2017)
Phase I and Preliminary Phase II Study ofTRC105in Combination with Sorafenib in Hepatocellular Carcinoma
Austin G. Duffy et al.
CLINICAL CANCER RESEARCH (2017)
Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma
Adrian Ally et al.
CELL (2017)
Randomized phase II placebo controlled study of codrituzumab in previously treated patients with advanced hepatocellular carcinoma
Ghassan K. Abou-Alfa et al.
JOURNAL OF HEPATOLOGY (2016)
Immunoglobulin Transporting Receptors Are Potential Targets for the Immunity Enhancement and Generation of Mammary Gland Bioreactor
Xuemei Jiang et al.
FRONTIERS IN IMMUNOLOGY (2016)
A novel anti-cancer agent Icaritin suppresses hepatocellular carcinoma initiation and malignant growth through the IL-6/Jak2/Stat3 pathway
Hong Zhao et al.
ONCOTARGET (2015)
A phase 1 open-label, sequential dose-escalation study investigating the safety, tolerability, and pharmacokinetics of intravenous TLC388 administered to patients with advanced solid tumors
Sharad Ghamande et al.
INVESTIGATIONAL NEW DRUGS (2014)
The c-Met Inhibitor MSC2156119J Effectively Inhibits Tumor Growth in Liver Cancer Models
Friedhelm Bladt et al.
CANCERS (2014)
Hepatocellular Carcinoma from an Immunologic Perspective
Tim F. Greten et al.
CLINICAL CANCER RESEARCH (2013)
Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study
Philip J. Johnson et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Brivanib in Patients With Advanced Hepatocellular Carcinoma Who Were Intolerant to Sorafenib or for Whom Sorafenib Failed: Results From the Randomized Phase III BRISK-PS Study
Josep M. Llovet et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Sunitinib Versus Sorafenib in Advanced Hepatocellular Cancer: Results of a Randomized Phase III Trial
Ann-Lii Cheng et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Targeting the HGF-cMET Axis in Hepatocellular Carcinoma
Neeta K. Venepalli et al.
INTERNATIONAL JOURNAL OF HEPATOLOGY (2013)
Phase I Trial of a Glypican-3-Derived Peptide Vaccine for Advanced Hepatocellular Carcinoma: Immunologic Evidence and Potential for Improving Overall Survival
Yu Sawada et al.
CLINICAL CANCER RESEARCH (2012)
MET: a promising anticancer therapeutic target
Solange Peters et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2012)
Icariin and its derivative, ICT, exert anti-inflammatory, anti-tumor effects, and modulate myeloid derived suppressive cells (MDSCs) functions
Junmin Zhou et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2011)
Integrative Transcriptome Analysis Reveals Common Molecular Subclasses of Human Hepatocellular Carcinoma
Yujin Hoshida et al.
CANCER RESEARCH (2009)
Transforming growth factor-β1 triggers hepatocellular carcinoma invasiveness via α3β1 integrin
G Giannelli et al.
AMERICAN JOURNAL OF PATHOLOGY (2002)
Share Paper
